Adc Therapeutics SA (ADCT) concluded trading on Wednesday at a closing price of $2.22, with 5.11 million shares of worth about $11.35 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -29.75% during that period and on December 11, 2024 the price saw a loss of about -36.21%. Currently the company’s common shares owned by public are about 96.69M shares, out of which, 77.83M shares are available for trading.
Stock saw a price change of 7.25% in past 5 days and over the past one month there was a price change of -25.50%. Year-to-date (YTD), ADCT shares are showing a performance of 33.73% which increased to 122.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.98 but also hit the highest price of $6.04 during that period. The average intraday trading volume for Adc Therapeutics SA shares is 598.43K. The stock is currently trading -6.17% below its 20-day simple moving average (SMA20), while that difference is down -19.74% for SMA50 and it goes to -35.90% lower than SMA200.
Adc Therapeutics SA (NYSE: ADCT) currently have 96.69M outstanding shares and institutions hold larger chunk of about 68.81% of that.
The stock has a current market capitalization of $214.65M and its 3Y-monthly beta is at 1.48. It has posted earnings per share of -$2.40 in the same period. It has Quick Ratio of 4.68. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADCT, volatility over the week remained 33.01% while standing at 15.58% over the month.
Stock’s fiscal year EPS is expected to rise by 41.93% while it is estimated to increase by 10.79% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stephens on November 08, 2024 offering an Overweight rating for the stock and assigned a target price of $6 to it. Stock get an Underperform rating from BofA Securities on April 24, 2023.
